Patient Selection and Personalized Treatment Strategies

Key Takeaways

• Transitioning from IV to oral medications requires careful management of adherence, side effects, and therapeutic efficacy to ensure optimal patient outcomes.
• Patient-specific factors, such as comorbidities and drug interactions, are critical in optimizing treatment during the transition from IV to oral medications.
• HER2-directed therapies benefit NSCLC patients with HER2 mutations or overexpression, necessitating molecular testing for accurate patient identification.
• A personalized approach, considering genetic profiles and overall health, is essential for maximizing the benefits of HER2-targeted therapies in NSCLC patients.